Alpha Tau Medical Ltd. (DRTSW) Aandelenanalyse

Bedrijfsoverzicht

Alpha Tau Medical Ltd. is a clinical-stage oncology therapeutics company dedicated to the research, development, and commercialization of diffusing alpha-emitters radiation therapy, specifically known as Alpha DaRT, for the treatment of solid tumors. Although the specific sector and industry classifications are not currently disclosed in the available data, the company operates within the specialized healthcare landscape focused on advanced cancer therapies and nuclear medicine applications. The firm employs a workforce of 121 individuals, reflecting a lean organizational structure typical of early-stage biotechnology entities. Given that the market capitalization, annual revenue, and forward P/E metrics are listed as unavailable, the financial scale of the company cannot be quantified through standard valuation multiples, suggesting the entity is likely in a pre-revenue or early commercialization phase where traditional scaling metrics have not yet been established. This lack of historical revenue and market cap data indicates that the company is currently prioritizing capital allocation toward clinical trial progression rather than generating immediate sales volume or establishing a mature market position.

Financiële gezondheid

The financial performance of Alpha Tau Medical Ltd. for the trailing twelve months reports a net income of $-42,627,000 and an EBITDA of $-41,056,000, while total revenue is unavailable in the current dataset. The substantial gap between the reported revenue (which is not listed) and the significant net loss reveals a cost structure dominated by research and development expenditures typical of clinical-stage biotechs, where operating expenses far exceed current sales. The company generated a free cash flow of $-19,703,876, indicating a net burn rate that consumes the company's liquid assets. All three margin metrics—gross margin, operating margin, and profit margin—are reported at 0.0%, which reflects the absence of recorded revenue or sales in the trailing twelve months, a common characteristic for companies that have not yet achieved commercial product launch. The company holds $73.13M in cash against $13.73M in debt, resulting in a debt-to-equity ratio of 17.80, which suggests a balance sheet that is highly leveraged relative to its equity base but maintains significant cash reserves to fund operations. A current ratio of 7.45 demonstrates that the company possesses ample short-term liquidity to cover its immediate obligations without reliance on external financing in the near term. Furthermore, the return on equity stands at -61.0% and the return on assets is -27.6%, metrics that mathematically result from the negative net income and indicate that management is currently utilizing the company's capital base to fund loss-generating activities rather than producing positive returns on invested capital.

Waarderingsbeoordeling

The trailing P/E ratio and forward P/E are both listed as unavailable, a standard presentation for companies that have not yet reported profitable earnings or have suspended reporting of these multiples during their clinical development stages. The price-to-book ratio is recorded at 0.94, indicating that the market valuations the company's equity at a discount relative to its book value, which often occurs in biotechnology firms with significant intangible assets or R&D costs that have not yet been fully capitalized or monetized. Because revenue is unavailable, the price-to-sales ratio and EV/EBITDA multiples are also listed as N/A, rendering traditional sales-based or earnings-based valuation comparisons with mature peers impossible at this stage of the company's lifecycle. The stock has traded within a 52-week range between a high of $0.86 and a low of $0.77, meaning the current trading price sits between these specific thresholds, bounded by the highest and lowest points observed over the last year. The beta value is 1.05, which signifies that the stock's price volatility is slightly higher than the broader market, moving with a slight premium to market fluctuations during periods of increased investor sentiment volatility.

Growth & Income

Revenue growth year-over-year and earnings growth year-over-year are both listed as unavailable, precluding any analysis of the trajectory between earnings and revenue expansion as the company has not yet generated significant commercial sales. Since the dividend yield and payout ratio are unavailable, the company is classified as a non-dividend payer, a strategic choice common for clinical-stage firms that reinvest all available capital back into research programs rather than distributing income to shareholders. The absence of dividend payments and the lack of positive earnings growth rates imply that the company's capital allocation strategy is entirely focused on sustaining clinical trials and advancing its Alpha DaRT technology rather than providing current income to investors. The overall growth and income profile for Alpha Tau Medical Ltd. is characterized by a complete reliance on external capital markets to fund operations, with zero reliance on organic revenue growth or dividend distributions to support shareholder returns.